These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37578664)

  • 1. Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study.
    Yoshida N; Kuriu Y; Ikeda J; Kudou M; Kirishima T; Okayama T; Miyagawa K; Takagi T; Nakanishi M; Doi T; Ishikawa T; Itoh Y; Otsuji E
    Int J Clin Oncol; 2023 Oct; 28(10):1378-1387. PubMed ID: 37578664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Exploration of Trifluridine/Tipiracil Monotherapy and in Combination With Bevacizumab or Immune Checkpoint Inhibitors for Patients With Metastatic Colorectal Cancer: A Real-World Study.
    Nie C; Xu W; Chen B; Lv H; Wang J; Liu Y; He Y; Wang S; Zhao J; Chen X
    Clin Colorectal Cancer; 2023 Mar; 22(1):76-84. PubMed ID: 36564281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy.
    Matsuoka S; Fujii H; Iihara H; Ohata K; Hirose C; Watanabe D; Sadaka S; Kiyama S; Makiyama A; Takahashi T; Kobayashi R; Matsuhashi N; Suzuki A
    Anticancer Res; 2023 May; 43(5):2351-2357. PubMed ID: 37097664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study.
    Li RR; Zhou HJ; Zeng DY; Jiang SF; Liu W; Frühling P; Liu ZY
    J Gastrointest Oncol; 2024 Apr; 15(2):612-629. PubMed ID: 38756644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series.
    Voutsadakis IA
    Curr Oncol; 2023 May; 30(6):5227-5239. PubMed ID: 37366880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study).
    Satake H; Kato T; Oba K; Kotaka M; Kagawa Y; Yasui H; Nakamura M; Watanabe T; Matsumoto T; Kii T; Terazawa T; Makiyama A; Takano N; Yokota M; Okita Y; Matoba K; Hasegawa H; Tsuji A; Komatsu Y; Yoshino T; Yamazaki K; Mishima H; Oki E; Nagata N; Sakamoto J
    Oncologist; 2020 Dec; 25(12):e1855-e1863. PubMed ID: 32666647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan.
    Kagawa Y; Shinozaki E; Okude R; Tone T; Kunitomi Y; Nakashima M
    ESMO Open; 2023 Aug; 8(4):101614. PubMed ID: 37562196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
    Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
    Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
    Martínez-Lago N; Chucla TC; De Castro BA; Ponte RV; Rendo CR; Rodriguez MIG; Diaz SS; Suarez BG; de la Cámara Gomez J; Fernández FB; Salvador MM; Lopez MR
    Sci Rep; 2022 Aug; 12(1):14612. PubMed ID: 36028552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial.
    Pfeiffer P; Yilmaz M; Möller S; Zitnjak D; Krogh M; Petersen LN; Poulsen LØ; Winther SB; Thomsen KG; Qvortrup C
    Lancet Oncol; 2020 Mar; 21(3):412-420. PubMed ID: 31999946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of trifluridine/tipiracil (TAS-102) in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
    Huang F; Yang H; Bao W; Bin Y; Zhou S; Wang M; Lv X
    Clin Transl Oncol; 2024 Feb; 26(2):468-476. PubMed ID: 37414979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer in the United States.
    Nevala-Plagemann C; Sama S; Ying J; Shen J; Haaland B; Florou V; Garrido-Laguna I
    J Natl Compr Canc Netw; 2023 Feb; 21(3):257-264. PubMed ID: 36812939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
    André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.
    Kwakman JJM; Vink G; Vestjens JH; Beerepoot LV; de Groot JW; Jansen RL; Opdam FL; Boot H; Creemers GJ; van Rooijen JM; Los M; Vulink AJE; Schut H; van Meerten E; Baars A; Hamberg P; Kapiteijn E; Sommeijer DW; Punt CJA; Koopman M
    Int J Clin Oncol; 2018 Jun; 23(3):482-489. PubMed ID: 29204933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
    Jalali A; Gard G; Banks S; Dunn C; Wong HL; Wong R; Lee M; Gately L; Loft M; Shapiro JD; Kosmider S; Tie J; Ananda S; Yeung JM; Jennens R; Lee B; McKendrick J; Lim L; Khattak A; Gibbs P
    Curr Probl Cancer; 2022 Apr; 46(2):100793. PubMed ID: 34565601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and Efficacy of TAS-102 with Bevacizumab for the Treatment of Unresectable Metastatic Colorectal Cancer - A Case Report].
    Arakawa S; Horiguchi A; Tomishige H; Kawabe N; Nagata H; Ishihara S; Ito M; Asano Y; Ito R; Isetani M; Shimizu K; Kamio K; Kawai T; Yasuoka H; Imaeda Y
    Gan To Kagaku Ryoho; 2018 Apr; 45(4):649-651. PubMed ID: 29650823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer.
    Yoshida Y; Sakamoto R; Kajitani R; Munechika T; Matsumoto Y; Komono A; Aisu N; Daibo K; Kiyomi F; Hasegawa S
    Anticancer Res; 2018 Jul; 38(7):4367-4373. PubMed ID: 29970575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
    Carriles C; Jimenez-Fonseca P; Sánchez-Cánovas M; Pimentel P; Carmona-Bayonas A; García T; Carbajales-Álvarez M; Lozano-Blázquez A
    Clin Transl Oncol; 2019 Dec; 21(12):1781-1785. PubMed ID: 31209792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study.
    Yoshida Y; Yamada T; Kamiyama H; Kosugi C; Ishibashi K; Yoshida H; Ishida H; Yamaguchi S; Kuramochi H; Fukazawa A; Sonoda H; Yoshimatsu K; Matsuda A; Hasegawa S; Sakamoto K; Otsuka T; Koda K;
    Int J Clin Oncol; 2021 Jan; 26(1):111-117. PubMed ID: 33083913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.